Politics By Andrew Joseph In their words: Warren, Buttigieg, Klobuchar, and other Democrats explain exactly how they’d lower drug prices
Off the Charts By Jennifer Adaeze Okwerekwu As medical professionals, my husband and I know the Nigerian travel ban is cruel. Now the pain is personal
Politics By Nicholas Florko More than a dozen Democrats are bringing people with sky-high insulin bills to the State of the Union
Politics By Megan Thielking A new push aims to bring mental health and addiction into the 2020 campaign conversation
Politics By Erin Mershon HHS hints at major changes to Medicare that could mean higher costs for patients
Politics By Lev Facher These Republicans campaigned on a bold drug-pricing pledge. Since they won, they’ve gone silent
Politics By Lev Facher Trump urges people to avoid discretionary travel and limit gatherings to fewer than 10 people
Politics By Lev Facher Elbow bumps, social distancing, and Medicare for All: The coronavirus pandemic dominated every aspect of the Democratic debate
Politics By Lev Facher ‘Reject Big Pharma’: Anti-vaccine activists co-opt a populist slogan to try to repeal a state immunization law
Pharmalot By Ed Silverman Pharmalittle: Purdue bankruptcy sets tone for opioid cases; Sanders criticizes Biden for praising pharma
Politics By Lev Facher and Ed Silverman VA declines broad coverage for new J&J depression drug touted by Trump
Pharma By Priyanka Dayal McCluskey — Boston Globe WHO rescinds opioid guidelines following criticism by two U.S. lawmakers
The Pharmalot View By Ed Silverman Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator
Politics By Rick Berke A letter from Executive Editor Rick Berke: All eyes on today’s drug pricing hearing
Politics By Nicholas Florko Defending the middlemen: JC Scott on testifying before Congress, challenging Trump, and revamping PBMs’ image
Heavyweights By Rick Berke Billionaire Sean Parker calls China’s gene-edited babies ‘Sputnik 2.0,’ praises FDA, and offers career advice for millennials
Biotech By Damian Garde, Rebecca Robbins, and Adam Feuerstein A tweet from Alexandria Ocasio-Cortez prompts a deeper debate over how drugs are made
Pharmalot By Ed Silverman Sanders accuses a drug maker of ‘immoral exploitation’ for the price of a rare disease drug
Pharmalot By Ed Silverman Here’s how Massachusetts officials hope to lower their Medicaid drug spending
Politics By Robert Weisman — Boston Globe Drug costs plague seniors, but legislative relief may be elusive
Pharmalot By Ed Silverman Big drug makers are socking away more cash lately thanks to the tax overhaul, and it’s likely to be used for more deals
Pharmalot By Ed Silverman New U.S. trade deal with Canada and Mexico is criticized for provisions affecting drug prices
Pharmalot By Elizabeth Cooney Pharmalittle: Markups on generics are growing; drug-pricing rhetoric heats up
Politics By Lev Facher Is mistrust of ‘big pharma’ enough to help unseat a Democratic stalwart in Congress?
Politics By Lev Facher NIH is investigating researchers who might have failed to disclose contributions from foreign governments
Opinions Plus By Elizabeth Cooney Public distrust is high, PBMs are the problem, but the future is bright: a survey of biopharma pros